Introduction

The mortality rate due to cancer has continued to increase over the last 50 years in Japan. Within the last 25 years, carcinoma has become the leading cause of death in Japan, with the rate of people dying from oral and pharyngeal carcinoma increasing about 3-fold\(^1\). Since some types of cancer develop from precancerous lesions, early diagnosis and timely treatment of such precancerous lesions can prevent their malignant transformation. Oral leukoplakia is noted to be the most common premalignant lesion of the oral mucosa\(^2\) and it is therefore important to clarify its clinical and histopathological characteristics. However, the mechanism of malignant transformation remains unknown. In this review, we focus on the relationship between the clinical and histopathological characteristics of oral leukoplakia and its malignant transformation.

Definition of oral leukoplakia

Oral leukoplakia is defined as a predominantly white lesion of the oral mucosa that can not be characterized...
as any other definable lesion. This very broad definition has led a number of clinicians to report their own classification criteria, although the general concept and the essential substance of oral leukoplakia have remained unchanged for a long time. Pindborg et al.2 state that leukoplakia should be used only as a clinical term, and we assert that final diagnosis is confirmed histopathologically by biopsy. Lesions that are diagnosed histologically as cancer are to be excluded from cases of leukoplakia.

**Clinical classification of oral leukoplakia**

The clinical and histological aspects of oral leukoplakia were rarely reported prior to the findings of Pindborg et al.7. Axell et al.3 and Pindborg et al.2 classified homogenous and non-homogenous leukoplakias into 4 subtypes for each. Homogenous types were classified into flat, corrugated, wrinkled, and pumice types, whereas non-homogenous types were classified as verrucous, nodular (speckled), ulcerated, and erythroleukoplakia types. The pumice type of leukoplakia was most-ly associated with tobacco smoking. Generally, non-homogenous types are considered to show a greater risk of malignant transformation. We previously classified oral leukoplakia into 4 clinical types: type I, flat white patch or plaque without red component; type II, flat white patch or plaque with red components; type III, slightly raised or elevated white plaque; and type IV, markedly raised or elevated white plaque (Table 1, Fig. 1 (A–D). Fig. 2 (A–C) are representative examples of epithelial dysplasia we used in the studies. We classifi ed oral leukoplakia into 4 clinical types based on our experience.

<table>
<thead>
<tr>
<th>Type I</th>
<th>Type II</th>
<th>Type III</th>
<th>Type IV</th>
</tr>
</thead>
<tbody>
<tr>
<td>flat, white patch/plaque without red components</td>
<td>flat, white patch/plaque with erosion or red components</td>
<td>slightly raised or elevated white patch/plaque</td>
<td>markedly raised or elevated white patch/plaque</td>
</tr>
</tbody>
</table>

We classified oral leukoplakia into 4 clinical types based on our experience.

**Relationship between clinical classification of leukoplakia and epithelial dysplasia**

Sharp5, Rotter et al.10 and Hahn et al.11 reported that verrucous leukoplakia was often associated with epithelial dysplasia, and Ackermann and Johnson12 and Shafer and Waldron13 stated that a pinkish-gray or red granular appearance was often associated with epithelial dysplasia or carcinoma in situ. Pindborg et al.7 confirmed that speckled leukoplakia, which is characterized by the presence of white patches in a nodular form or white lesions interspersed with erythematous area, was often associated with epithelial dysplasia or carcinoma. These findings were supported by subsequent reports showing the association of non-homogenous leukoplakia with epithelial dysplasia14–16. Sugár and Báńoczy17, using a different clinical classification, also reported the association of leukoplakia erosiva and leukoplakia verrucosa with epithelial dysplasia. Because the clinical manifestations of oral leukoplakia in Japan did not exactly match these classification systems (there are few cases with nodular appearance in Japan), we constructed our own classification system, as mentioned above, in which type II oral leukoplakia included an ulcerated type or erythroleukoplakia. We found that the occurrence of epithelial dysplasia was highly associated with type II leukoplakia, followed by type III or IV (Table 2).19–20

**Malignant transformation rate versus cumulative malignant transformation rate**

Previously reported rates of malignant transformation of oral leukoplakia range from 0.13 to 17.0% (Table 3).18,20–33 Our recent study showed that the malignant transformation rate of oral leukoplakia was 7.9% (35 of 444 patients with oral leukoplakia)20. However, the rate of malignant transformation may increase when patients are followed over a longer term or may decrease when patients are lost early to follow-up. The resulting rate of malignant transformation can therefore be unreliable. To eliminate this bias, the calculation of cumulative survival rate is necessary to determine the cumulative malignant transformation rate. The cumulative transformation rates reported by some researchers are shown in Table 4. The 5-year cumulative malignant transformation rate ranged from 1.2 to 14.5% 9,25,32,34–37.
Fig. 1 Clinical features of leukoplakia can be classified into four types, type I (A) of the maxillary gingiva showing flat white patch, type II (B) of the tongue showing white patch and plaque with erosion, type III (C) of the buccal mucosa showing slightly elevated white plaque, and type IV (D) of the buccal mucosa showing markedly elevated white plaque with partly granular appearance.

Fig. 2 Histopathological features of leukoplakia. Mild dysplasia (A): Slight irregular epithelial architecture limited to the lower third of the epithelium. Basal-parabasal cells show hypochromatic large nuclei and loss of polarity. Moderate dysplasia (B): Hyperplastic epithelium with increased number of polymorphic cells extends up to two thirds of the epithelium, and cellular atypia is more pronounced with nuclear pleomorphism. Severe dysplasia (C): The atypical basal-like and spinous-like cells occupy almost all epithelial layers. Squamous epithelium is of variable thickness with drop-shaped rete ridges and prominent cytologic atypia.
A large number of reports of oral leukoplakia, regardless of malignant transformation, identified a male predominance, with a female predominance reported in only a few. Sex predilection for malignant transformation is unclear because of the conflicting data reported in the literature. Lind reported that females were more prone

Gender and malignant transformation

A large number of reports of oral leukoplakia, regardless of malignant transformation, identified a male predominance, with a female predominance reported in only a few. Sex predilection for malignant transformation is unclear because of the conflicting data reported in the literature. Lind reported that females were more prone
to undergo malignant transformation than males, and epithelial dysplasia was more frequent in females. This was further supported by the findings of other authors. The risk factors for malignant transformation were listed by Schepman et al. (1998) as follows: female gender, absence of smoking habits in women ($p < 0.05$), and non-homogenous clinical aspect ($p < 0.01$). However, other reports found a greater malignant transformation potential among males in India, particularly in association with chewing tobacco and smoking habits. In our study, the malignant transformation rate (11.2%) of females with leukoplakia was higher than that (6.2%) of males (Table 5). However, this did not represent a significant statistical difference for gender.

### Table 5

<table>
<thead>
<tr>
<th>Age</th>
<th>Male</th>
<th>Female</th>
<th>Total</th>
<th>(%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>18–19</td>
<td>0/ 2</td>
<td>0/ 0</td>
<td>0/ 2</td>
<td>(0.0)</td>
</tr>
<tr>
<td>20–29</td>
<td>0/ 12</td>
<td>1/ 7</td>
<td>1/ 19</td>
<td>(5.3)</td>
</tr>
<tr>
<td>30–39</td>
<td>1/ 24</td>
<td>1/ 14</td>
<td>2/ 38</td>
<td>(5.3)</td>
</tr>
<tr>
<td>40–49</td>
<td>1/ 52</td>
<td>1/ 34</td>
<td>2/ 86</td>
<td>(2.3)</td>
</tr>
<tr>
<td>50–59</td>
<td>6/ 90</td>
<td>6/ 58</td>
<td>12/148</td>
<td>(8.1)</td>
</tr>
<tr>
<td>60–69</td>
<td>7/ 62</td>
<td>7/ 31</td>
<td>14/ 93</td>
<td>(15.1)</td>
</tr>
<tr>
<td>70–79</td>
<td>1/ 29</td>
<td>1/ 23</td>
<td>2/ 52</td>
<td>(5.8)</td>
</tr>
<tr>
<td>80</td>
<td>1/ 4</td>
<td>1/ 2</td>
<td>2/ 6</td>
<td>(33.0)</td>
</tr>
</tbody>
</table>

| Total | 17/275| 18/169 | 35/444| (7.9) |

*Statistically significant difference of malignant transformation rate between the over 50-year-old group and the under 50-year-old group ($p < 0.05$).

### Site and malignant transformation

Our findings showed that the malignant transformation rate of oral leukoplakia of the tongue was significantly higher than that of the buccal mucosa and that of other sites (Table 6). These results concur with those of other studies conducted in Japan. Some authors also reported that leukoplakia of the tongue and floor of the mouth exhibited a high risk of malignant transformation. This is in contrast to other reports identifying the buccal mucosa and labial commissure as the areas with the highest malignant transformation rate, particularly for patients with tobacco chewing and smoking habits among Indian villagers. On the other hand, some reports showed that no oral subsites are associated with a high risk of malignant transformation. These differences might be related to the presence or absence of various oral habits of certain groups or populations.

### Clinical type and malignant transformation

Since Pinborg et al. showed that speckled leukoplakia was often associated with epithelial dysplasia and carcinoma, various reports about the correlation of the clinical type of oral leukoplakia with malignant transformation have been published. Sugár and Bánóczy reported that erosive leukoplakia showed the highest potential of malignant transformation in comparison to simplex leukoplakia. Holmstrup et al. examined 236 patients with leukoplakia and using logistic regression analysis showed a 7-fold increase in the risk of malignant transformation (OR = 7.0) in non-homoge-

### Age and malignant transformation

Over a 30-year period, Bánóczy identified a greater prevalence of leukoplakia among the 50–60 year-old group, but the risk of malignant transformation was highest among the 60–70 year-old group. Our study also showed a statistically significant difference of malignant transformation rate between the over 50-year-old group and the under 50-year-old group (Table 5), supporting the findings of Chiesa et al. with statistical significance. The relationship between higher malignant transformation rate and older patients may suggest that patients with longer exposure to oral leukoplakia are more prone to malignant transformation.
nous leukoplakia as compared to homogenous leukopla-
kia, and a 5.4-fold increase in the risk when the lesions exceeded 200 mm². In our classification, malignant
transformation rate was the highest in type II lesions (21.4%), followed by type III (6.9%) and type IV (6.7%),
with type I (2.8%) the lowest (Table 6)²⁰. There were
statistical differences between type II and type I, be-
tween type II and types III and IV, and between type I
and types II, III and IV²⁰. Despite the fact that various criteria are used to evalu-
ate the clinical types of oral leukoplakia, we concur that
leukoplakia with red components and the so-called non-
homogenous leukoplakia, including verrucous and
raised type, carry a higher risk of malignant transfor-
mation.

**Epithelial dysplasia and malignant transforma-
tion**

The incidences of malignant transformation of oral
leukoplakia with and without dysplasia are listed in Ta-
ble 7¹⁵,¹⁶,¹⁸,²⁰,⁴⁶⁻⁴⁸. Our study²⁰ showed that 28 (13.3%) of
210 patients having leukoplakia with epithelial dyspla-
sia underwent malignant transformation, though only 7
(3.0%) of 234 patients with leukoplakia showing no epi-
thelial dysplasia had malignant transformation. There
was a statistical difference between the malignant
transformation rate of the oral leukoplakia with epithel-
ial dysplasia and that without dysplasia. However,
there was no correlation between the malignant trans-
formation rate and degree of epithelial dysplasia (Table
8)²⁰, because the leukoplakias with moderate and severe
dysplasia were selectively and immediately excised.
Some studies also showed that the malignant transfor-
mation rate of oral leukoplakia with epithelial dysplasia
was higher than that of oral leukoplakia without epi-
thelial dysplasia¹⁸,⁴⁸. Kawabe et al.³⁷, using the Cox pro-
portional hazard model, reported that only the presence
of epithelial dysplasia and a previous history of oral
cancer are significant predictors for the malignant
transformation of leukoplakia.

On the contrary, Holmstrup et al.¹³ reported that the
presence of epithelial dysplasia in oral leukoplakia was
not a statistically significant factor for malignant trans-
formation based on logistic regression analysis. They
described that this factor may, however, vary in levels of
significance due to the subjectivity of diagnosis of epi-
thelial dysplasia⁴⁹⁻⁵¹.

The periods from initial biopsy of oral leukoplakia to
malignant transformation were examined in our study

<table>
<thead>
<tr>
<th>Site</th>
<th>I</th>
<th>II</th>
<th>III</th>
<th>IV</th>
<th>Total (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tongue</td>
<td>8/ 93</td>
<td>14/40</td>
<td>0/ 6</td>
<td>2/ 7</td>
<td>24/143 (16.4)</td>
</tr>
<tr>
<td>Buccal</td>
<td>1/ 89</td>
<td>4/23</td>
<td>1/ 4</td>
<td>0/ 9</td>
<td>6/125 (4.8)</td>
</tr>
<tr>
<td>Lower gum</td>
<td>4/129</td>
<td>0/7</td>
<td>1/7</td>
<td>0/ 7</td>
<td>5/150 (3.3)</td>
</tr>
<tr>
<td>Upper gum</td>
<td>0/ 80</td>
<td>0/ 5</td>
<td>0/ 3</td>
<td>0/ 5</td>
<td>0/93 (0.0)</td>
</tr>
<tr>
<td>Palate</td>
<td>0/ 34</td>
<td>0/ 5</td>
<td>0/ 4</td>
<td>0/ 2</td>
<td>0/45 (0.0)</td>
</tr>
<tr>
<td>Floor of mouth</td>
<td>0/ 22</td>
<td>0/ 2</td>
<td>0/ 4</td>
<td></td>
<td>0/28 (0.0)</td>
</tr>
<tr>
<td>Lips</td>
<td>0/ 8</td>
<td>0/ 1</td>
<td>0/ 1</td>
<td></td>
<td>0/10 (0.0)</td>
</tr>
<tr>
<td>Oropharynx</td>
<td>0/ 3</td>
<td>0/ 1</td>
<td></td>
<td></td>
<td>0/ 4 (0.0)</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>13/458</td>
<td>18/84</td>
<td>2/29</td>
<td>2/30</td>
<td>35/601 (5.8)</td>
</tr>
</tbody>
</table>

* Statistically significant differences of malignant transformation rate of leukoplakia between the tongue and
  buccal mucosa (p<0.01), and between the buccal mucosa and other sites (p<0.01). There were statistically sign-
ificant differences between type II and type I (p<0.01), and between type II and types III and IV (p<0.05).
November, 2006          Oral Leukoplakia Related to Malignant Transformation

The shortest (less than 5 years) malignant transformation periods were observed for oral leukoplakia with severe dysplasia, followed by moderate epithelial dysplasia, mild dysplasia and no dysplasia from 5 years to a maximum 25 years 6 months. These findings suggest that there is a relationship between severity of epithelial dysplasia and the period of malignant transformation of oral leukoplakia to cancer development.

### Etiologic factors of oral leukoplakia

The pathogenesis of oral leukoplakia is likely to be associated with oral habits since many studies showed a relationship of smoking with leukoplakia and malignant transformation. A prospective epidemiologic house-to-house survey for randomly extracted samples in India showed that the annual incidence rate of leukoplakia was highest in the group with mixed tobacco habits (chewing and smoking) and was lowest in the group without any tobacco habits. The rate of malig-

---

**Table 7** Malignant transformation rates of oral leukoplakia with and without dysplasia as reported in the literature

<table>
<thead>
<tr>
<th>Authors</th>
<th>(Year)</th>
<th>No. of leukoplakia with epithelial dysplasia</th>
<th>No. of leukoplakia without epithelial dysplasia</th>
<th>Follow-up periods (yr)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mincer et al.</td>
<td>(1972)</td>
<td>45 5 (11.1)</td>
<td>165 612 (36.4)</td>
<td>Up to 8</td>
</tr>
<tr>
<td>Banoczky and Csiba</td>
<td>(1976)</td>
<td>68 9 (13.2)</td>
<td>234 8 (36.4)</td>
<td>1–20 (mean 6.3)</td>
</tr>
<tr>
<td>Pindborg et al.</td>
<td>(1977)</td>
<td>61 4 (6.6)</td>
<td>235 7 (16.0)</td>
<td>Up to 7</td>
</tr>
<tr>
<td>Silverman et al.</td>
<td>(1984)</td>
<td>22 8 (36.4)</td>
<td>235 23 (9.8)</td>
<td>Mean 8.1</td>
</tr>
<tr>
<td>Lumerman et al.</td>
<td>(1995)</td>
<td>44 7 (16.0)</td>
<td>235 7 (3.0)</td>
<td>1–25</td>
</tr>
<tr>
<td>Amagasa et al.</td>
<td>(1999)</td>
<td>210 28 (13.3)</td>
<td>235 17 (7.7)</td>
<td>Over 20</td>
</tr>
<tr>
<td>Cowan et al.</td>
<td>(2001)</td>
<td>165 25 (15.0)</td>
<td>1182 7 (1.0)</td>
<td>Over 20</td>
</tr>
</tbody>
</table>

The malignant transformation rates of leukoplakia with dysplasia were higher than those without dysplasia.

**Table 8** Incidence of malignant transformation of oral leukoplakias according to epithelial dysplasia

<table>
<thead>
<tr>
<th>Epithelial dysplasia</th>
<th>No. of cases</th>
<th>No. of malignant transformation (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td>234</td>
<td>7 (3.0)</td>
</tr>
<tr>
<td>Mild</td>
<td>138</td>
<td>18 (13.0)</td>
</tr>
<tr>
<td>Moderate</td>
<td>49</td>
<td>7 (14.3)</td>
</tr>
<tr>
<td>Severe</td>
<td>23</td>
<td>3 (13.0)</td>
</tr>
</tbody>
</table>

Total 444 35 (7.9)

**Table 9** Malignant transformation periods of 35 cases of oral leukoplakias according to epithelial dysplasia

<table>
<thead>
<tr>
<th>Epithelial dysplasia</th>
<th>≤ 2</th>
<th>≤ 5</th>
<th>≤ 7</th>
<th>≤ 10</th>
<th>10 &lt;</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>5</td>
<td>1</td>
<td>7</td>
</tr>
<tr>
<td>Mild</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>4</td>
</tr>
<tr>
<td>Moderate</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td>Severe</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>3</td>
</tr>
</tbody>
</table>

Total (%): 6 (17.2) 12 (34.3) 6 (17.1) 7 (20.0) 4 (11.4) 35 (100.0)
nant transformation was also highest in oral leukoplakia associated with tobacco chewing habits. A case control study performed in Taiwan showed that adjusted odds ratios for betel nut chewing and smoking on the occurrence of leukoplakia were 17.43 (95% CI 1.94–156.27) and 3.22 (95% CI 1.06–9.78), respectively. Moreover, the cessation of smoking is expected to reduce leukoplakia cases by 36%, while the elimination of betel nuts will prevent leukoplakia by 62% and malignant transformation to oral carcinoma by 26% in the underlying population.

Some authors have reported different findings, however. Schepman et al. reported that the parameters associated with an increased risk of malignant transformation were female gender (p<0.025), absence of smoking habits in women (p<0.05), and a non-homogeneous clinical aspect (p<0.01). Silverman et al. also showed that high risks for malignant transformation included non-smoking patients, the clinical presence of erythroplasia (erythroleukoplakia), and a clinical verrucous-papillary hyperkeratotic pattern.

Human papilloma virus (HPV) may also be implicated in oral leukoplakia as an infecting agent. Compared with normal oral mucosa, HPV is detected frequently in oral dysplasia lesions and carcinoma, and HPV infection with a high-risk genotype is well known to be an independent risk factor for oral cancer. The consistent absence of the malignant-type HPV in the betel quid-related lesions suggests that HPV plays only a minor role in betel quid-related carcinogenesis, although an association between the benign-type HPV with betel quid chewing may contribute to malignant transformation of oral mucosa.

From the above findings, it is suggested that there are several routes to malignant transformation of oral leukoplakia, including the transformations induced by the carcinogens in betel quid chewing and smoking, and by HPV infection. Further studies remain to be done.

### Treatment

The lack of randomized controlled trials comparing the different treatment modalities for oral leukoplakia is a major dilemma for oral and maxillofacial surgeons. Several comparative studies have reported that there are no effective treatment procedures to prevent malignant transformation of oral leukoplakia. The risk of cancer development could not be significantly reduced by surgical intervention. The malignant transformation rates of oral leukoplakia appeared to be lower in the patients diagnosed by health examination in India who had no treatment as compared with in-patients. Silverman et al. found only 6 cases of malignant transformation in 4,762 patients with oral leukoplakia receiving no treatment over a 2-year period. Nevertheless, as our previous findings showed that the malignant transformation rate of leukoplakia treated by surgery was significantly lower than that without any treatment (p<0.01) or that without surgery (p<0.01).

<table>
<thead>
<tr>
<th>Table 10</th>
<th>Malignant transformation rates according to treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment</td>
<td>No. of cases</td>
</tr>
<tr>
<td>Surgery</td>
<td>94</td>
</tr>
<tr>
<td>Chemotherapy</td>
<td>13</td>
</tr>
<tr>
<td>Chemotherapy and surgery</td>
<td>13</td>
</tr>
<tr>
<td>Radiation</td>
<td>5</td>
</tr>
<tr>
<td>None</td>
<td>44</td>
</tr>
<tr>
<td>Total</td>
<td>169</td>
</tr>
</tbody>
</table>

* Malignant transformation rate of leukoplakia treated by surgery was significantly lower than that without any treatment (p<0.01) or that without surgery (p<0.01).
other retinoids or topical bleomycin are used for the therapy of leukoplakia, these were reported to have only a limited effect in controlling oral leukoplakia and in preventing malignant transformation.

Acknowledgment

We would like to thank Dr. Nobuyuki Tanaka and Dr. Rodelio Augirre for their help in preparing this manuscript.

Reference

28. Silverman, Jr. S., and Rozen, RD.: Observations on the clinical characteristics and natural history of oral leukopla-
29. Banoczy, J.: Follow-up studies in oral leukoplakia: J Max-
32. Schepman K.P., van der Meij E.H., Smelee E.E., and van der Waal.: Malignant transformation of oral leukopla-
iak: a follow-up study of a hospital-based population of 166 pa-
33. Amagasa T., Fujiwara E., Hasegawa K., Shioda S.: Clinico-pa-
thology of Oral Cancer and Precancerous Lesions. Interna-
tional Congress of Oral Cancer (November 14, 1989. New Delhi, India).
35. Inoue A., Sakamoto A., Uchida M., and Kamata S.: Malig-
nant progression of oral leukoplakia. J Jpn Soc Cancer Ther 20: 18–24, 1985. (Abstract in English)
40. Chiesa F., Boracchi P., Tradati N., Rossi N., Costal L., Giardini R., Marazza M., and Zurrizda S.: Risk of prene-
oplastic and neoplastic events in operated oral leukopla-
41. Kramer I.R.H., El-Labban N., and Lee K.W.: The clinical features and risk of malignant transformation in sublin-
42. Pogrel M.A.: Sublingual keratosis and malignant transfor-
43. Holmstrup P., Vedtofte P., Reibel J., and Stolze K.: Long-
47. Lumberman H., Freedman P., and Kerpel S.: Oral epitheli-
54. Miller C.S., and White D.K: Human papillomavirus ex-
pression in oral mucosa, premalignant conditions and squamous cell carcinoma: a retrospective review of the litera-
ture. Oral Surg Oral Med Oral Pathol Oral Radiol En-


61. Lele S.: Although leukoplakia responds to some treatments relapses and adverse effects are common. Evid Based Dent 6: 15–16, 2005.


